Microbial inactivation properties of a new antimicrobialantithrombotic catheter lock solution (citratemethylene blueparabens)

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1937-1945

  Steczko, Janusz ^a   Ash, Stephen R ^a,b,c   Nivens, David E ^d   Brewer, Lloyd ^a   Winger, Roland K ^a  

^a R and D   (United States)

^b Clarian Arnett Health   (United States)

^c PURDUE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

Biofilm; Catheter infection; CRBSI; Haemodialysis; Lock solution

Indexed keywords

ANTIINFECTIVE AGENT; CITRATE SODIUM PLUS METHYL PARABEN PLUS METHYLENE BLUE PLUS PROPYL PARABEN; HEPARIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTICOAGULATION; ANTIMICROBIAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BIOFILM; CATHETER; CONTROLLED STUDY; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SCANNING ELECTRON MICROSCOPE;

ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIA; BIOFILMS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CITRIC ACID; ESCHERICHIA COLI; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; METHYLENE BLUE; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, SCANNING; PARABENS; PLANKTON; PSEUDOMONAS AERUGINOSA; RENAL DIALYSIS; STAINING AND LABELING; STAPHYLOCOCCUS AUREUS;

EID: 64649094132     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn776     Document Type: Article

References (60)

1. Tokars JI. Description of a new surveillance system for bloodstream and vascular access infections in outpatient hemodialysis centers. Semin Dial 2000; 13: 97-100
2. Allon M, Depner TA, Radeva M et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003; 14: 1863-1870
3. Finelli L, Miller JT, Tokars JI et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61
4. Klevens RM, Tokars JI, Andrus M. Electronic reporting of infections associated with hemodialysis. Nephrol News Issues 2005; 19: 37-38, 43
5. Weijmer MC, Van Den Dorpel MA, Van de Ven PJ et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2769-2777
6. McIntyre CW, Hulme LJ, Taal M et al. Locking of tunneled hemodialysis catheters with gentamicin and heparin. Kidney Int 2004; 66: 801-805
7. Dogra GK, Herson H, Hutchison B et al. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. JAm Soc Nephrol 2002; 13: 2133-2139
8. Johnson DW, MacGinley R, Kay TD et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17: 1802-1807
9. Lok CE, Stanley KE, Hux JE et al. Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 2003; 14: 169-179
10. Feely T, Copley A, Bleyer AJ. Catheter lock solutions to prevent bloodstream infections in high-risk hemodialysis patients. Am J Nephrol 2007; 27: 24-29
11. Kim SH, Song KI, Chang JW et al. Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: a prospective, randomized clinical trial. Kidney Int 2006; 69: 161-164
12. Saxena AK, Panhotra BR, Sundaram DS et al. Enhancing the survival of tunneled haemodialysis catheters using an antibiotic lock in the elderly: a randomised, double-blind clinical trial. Nephrology (Carlton) 2006; 11: 299-305
13. Nori US, Manoharan A, Thornby JI et al. Mortality risk factors in chronic haemodialysis patients with infective endocarditis. Nephrol Dial Transplant 2006; 21: 2184-2190
14. Bleyer AJ, Mason L, Russell G et al. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control Hosp Epidemiol 2005; 26: 520-524
15. Betjes MG, van Agteren M. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution. Nephrol Dial Transplant 2004; 19: 1546-1551
16. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. Nephrol Dial Transplant 2008; 23: 1666-1672
17. Jaffer Y, Selby NM, Taal MW et al. A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. Am J Kidney Dis 2008; 51: 233-241
18. Allon M. Prophylaxis against dialysis catheter-related bacteremia: a glimmer of hope. Am J Kidney Dis 2008; 51: 165-168
19. O'Grady NP, Alexander M, Dellinger EP et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002; 30: 476-489
20. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391-402
21. Polaschegg HD, Shah C. Overspill of catheter locking solution: safety and efficacy aspects. ASAIO J 2003; 49: 713-715
22. Guerraoui A, Dacosta EE, Roche BB et al. Emergence of multiresistant Staphylococcus epidermidis (MRSE) after lock antibiotic regimen by gentamicin in permanent hemodialysis catheters. Perspective study, 1999-2003 (Abstract). J Am Soc Nephrol 2004; 15: 368A
23. Karaaslan H, Peyronnet P, Benevent D et al. Risk of heparin lock-related bleeding when using indwelling venous catheter in haemodialysis. Nephrol Dial Transplant 2001; 16: 2072-2074
24. Bauer E, Derfler K, Joukhadar C et al. Citrate kinetics in patients receiving long-term hemodialysis therapy. Am J Kidney Dis 2005; 46: 903-907
25. Fux CA, Stoodley P, Hall-Stoodley L et al. Bacterial biofilms: a diagnostic and therapeutic challenge. Expert Rev Anti Infect Ther 2003; 1: 667-683
26. Manierski C, Besarab A. Antimicrobial locks: putting the lock on catheter infections. Adv Chronic Kidney Dis 2006; 13: 245-258
27. Lok CE. Avoiding trouble down the line: the management and prevention of hemodialysis catheter-related infections. Adv Chronic Kidney Dis 2006; 13: 225-244
28. Bleyer AJ. Use of antimicrobial catheter lock solutions to prevent catheter-related bacteremia. Clin J Am Soc Nephrol 2007; 2: 1073-1078
29. Standards NCfCL. M23-A2, vol. 21, no. 7. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000
30. Rosett W, Hodges GR. Antimicrobial activity of heparin. J Clin Microbiol 1980; 11: 30-34
31. Zappala C, Chandan S, George N et al. The antimicrobial effect of heparin on common respiratory pathogens. Crit Care Resusc 2007; 9: 157-160
32. Shanks RM, Donegan NP, Graber ML et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73: 4596-4606
33. Mandolfo S, Borlandelli S, Elli A. Catheter lock solutions: it's time for a change. J Vasc Access 2006; 7: 99-102
34. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant 2007; 22: 2239-2246
35. Weijmer MC, Debets-Ossenkopp YJ, Van De Vondervoort FJ et al. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002; 17: 2189-2195
36. Nori US, Manoharan A, Yee J et al. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 2006; 48: 596-605
37. Fernandez-Hidalgo N, Almirante B, Calleja R et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57: 1172-1180
38. Maya ID, Carlton D, Estrada E et al. Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2007; 50: 289-295
39. Stas KJ, Vanwalleghem J, De Moor B et al. Trisodium citrate 30% vs. heparin 5% as catheter lock in the interdialytic period in twin- or double-lumen dialysis catheters for intermittent haemodialysis. Nephrol Dial Transplant 2001; 16: 1521-1522
40. Ash SR, Mankus RA, Sutton JM et al. Concentrated sodium citrate (23%) for catheter lock. Hemodial Int 2000; 4: 22-31
41. Bayes B, Bonal J, Romero R. Sodium citrate for filling haemodialysis catheters. Nephrol Dial Transplant 1999; 14: 2532-2533
42. Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate. Nephrol Dial Transplant 2003; 18: 2688-2690
43. FDA. FDA issues warning on TriCitrasol dialysis catheter anticoagulant. April 2000
44. Branson PK, McCoy RA, Phillips BA et al. Efficacy of 1.4 percent sodium citrate in maintaining arterial catheter patency in patients in a medical ICU. Chest 1993; 103: 882-885
45. Buturovic J, Ponikvar R, Kandus A et al. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline. a prospective randomized study. Artif Organs 1998; 22: 945-947
46. Michaud D, Komant T, Pfefferle P. Four percent trisodium citrate as an alternative anticoagulant for maintaining patency of central venous hemodialysis catheters: case report and discussion. AmJCritCare 2001; 10: 351-354
47. Hendrickx L, Kuypers D, Evenepoel P et al. A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. Int J Artif Organs 2001; 24: 208-211
48. Meeus G, Kuypers DR, Claes K et al. A prospective, randomized, double-blind crossover study on the use of 5% citrate lock versus 10% citrate lock in permanent hemodialysis catheters. Blood Purif 2005; 23: 101-115
49. Grudzinski L, Quinan P, Kwok S et al. Sodium citrate 4% locking solution for central venous dialysis catheters - an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007; 22: 471-476
50. Lok CE, Appleton D, Bhola C et al. Trisodium citrate 4% - an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007; 22: 477-483
51. MacRae JM, Dojcinovic I, Djurdjev O et al. Citrate 4% versus Heparin and the Reduction of Thrombosis Study (CHARTS). Clin J Am Soc Nephrol 2008; 3: 369-374
52. Shanks RM, Sargent JL, Martinez RM et al. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21: 2247-2255
53. Wainwright M, Crossley KB. Methylene blue - a therapeutic dye for all seasons? J Chemother 2002; 14: 431-443
54. Wainwright M, Phoenix DA, Laycock SL et al. Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus. FEMS Microbiol Lett 1998; 160: 177-181
55. Usacheva MN, Teichert MC, Biel MA. Comparison of the methylene blue and toluidine blue photobactericidal efficacy against gram-positive and gram-negative microorganisms. Lasers Surg Med 2001; 29: 165-173
56. Rice L, Phoenix DA, Wainwright M et al. Effect of increasing methylation on the ability of methylene blue to cause diaphorase-catalysed oxidation of NADH. Biochem Soc Trans 1998; 26: S319
57. Usacheva MN, Teichert MC, Biel MA. The interaction of lipopolysaccharides with phenothiazine dyes. Lasers Surg Med 2003; 33: 311-319
58. Soni MG, Burdock GA, Taylor SL et al. Safety assessment of propyl paraben: a review of the published literature. Food Chem Toxicol 2001; 39: 513-532
59. Soni MG, Taylor SL, Greenberg NA et al. Evaluation of the health aspects of methyl paraben: a review of the published literature. Food Chem Toxicol 2002; 40: 1335-1373
60. Soni MG, Carabin IG, Burdock GA. Safety assessment of esters of p-hydroxybenzoic acid (parabens). Food Chem Toxicol 2005; 43: 985-1015